Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study

Exclusion Criteria

• •Patients taking COC for more than 4 weeks before inclusion in the study;
• •Patients with contraindications to the COC;
• •Decompensated liver disease severity class \> CPT A6;
• •Patients taking peg-IFN-alpha 2a;
• •Alcohol abuse according to the AUDIT-c questionnaire;
• •Pregnancy and lactation;
• •Patients with coinfection with HIV, HCV;
• •GFR ≤ 15 ml/min/1.73 m2;
• •Exclude patients with significant biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 norms;
• •Patients with other causes of liver damage;
• •Drug addict people;
• •Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than 5 times or more;
• •Patient takes part in an interventional clinical trial.